Saccharomyces cerevisiae as a platform for assessing sphingolipid lipid kinase inhibitors.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29672528.
- Also identified by DOI 10.1371/journal.pone.0192179 and PMC identifier 5908134.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Successful medicinal chemistry campaigns to discover and optimize sphingosine kinase inhibitors require a robust assay for screening chemical libraries and for determining rank order potencies. Existing assays for these enzymes are laborious, expensive and/or low throughput. The toxicity of excessive levels of phosphorylated sphingoid bases for the budding yeast, Saccharomyces cerevisiae, affords an assay wherein inhibitors added to the culture media rescue growth in a dose-dependent fashion. Herein, we describe our adaptation of a simple, inexpensive, and high throughput assay for assessing inhibitors of sphingosine kinase types 1 and 2 as well as ceramide kinase and for testing enzymatic activity of sphingosine kinase type 2 mutants. The assay was validated using recombinant enzymes and generally agrees with the rank order of potencies of existing inhibitors.
Medical subject headings
- Drug Evaluation, Preclinical
- Enzyme Inhibitors
- Phosphotransferases (Alcohol Group Acceptor)
- Saccharomyces cerevisiae